ADH-1 (Exherin™) is a pentapeptide, which competitively inhibits N-cadherin, resulting in vascular disruptive
effect of tumor vasculature in preclinical models. This study was designed to assess the toxicity of ADH-1 and to
determine the maximal tolerated dose (MTD).
Patients and Methods: Adult patients with advanced measurable solid tumors were stratified according to their tumor
N-cadherin status. ADH-1 was administered as a short infusion, every six weeks. Assessment of response was done
every 6 weeks. PK parameters included: estimated volume of distribution of the central compartment, the α and β phase
half-lives, area under the plasma concentration- time curve (AUC), clearance, and volume of distribution. Target lesions
were assessed by dynamic contrast enhancing- magnetic resonance imaging (DCE-MRI).
Results: 46 patients were enrolled, 25 (54%) had N-cadherin positive status. The doses administered ranged from 50
mg/m2 to 1000 mg/m2, and the MTD was not reached. The PK analysis of the concentration-time data displayed a
biphasic profile. Most of the toxicities were grade 1 and 2 with fatigue, nausea, chest pain and dysgeusia being the most
common. Eleven patients had disease control, the single patient who had partial response had N-cadherin positive tumor.
Conclusion: ADH-1 is a well tolerated drug with a modest anti tumor effect in tumors which express N-cadherin.